/BIAF
BIAF Stock - bioAffinity Technologies, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$1.24+2.06%
+$0.03 (+2.06%) • Dec 19
39
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.23
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.36
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BIAF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.23 – $1.25
TARGET (TP)$1.43
STOP LOSS$1.14
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.42
52W High$46.53
52W Low$1.18
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.36M | $2.53M | $4,803 | N/A | N/A |
| Gross Profit | $3.38M | $791,615 | $4,336 | $-4,817 | $-22,242 |
| Gross Margin | 36.1% | 31.3% | 90.3% | N/A | N/A |
| Operating Income | $-8,953,000 | $-7,973,000 | $-4,011,058 | $-2,206,822 | $-2,604,385 |
| Net Income | $-9,040,000 | $-7,937,000 | $-8,154,113 | $-6,326,413 | $-7,268,737 |
| Net Margin | -96.6% | -313.5% | -169771.2% | N/A | N/A |
| EPS | $-22.50 | $-27.30 | $-54.30 | $-25.80 | $-29.70 |
Company Overview
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BIAFBeat Rate
8%
Last 12 quarters
Avg Surprise
-22.7%
EPS vs Estimate
Beats / Misses
1/9
2 met exactly
Latest EPS
$-2.70
Q4 2025
EPS Surprise History
Q2 24
-30.0%
$-0.26vs$-0.20
Q2 24
-40.0%
$-0.21vs$-0.15
Q3 24
-11.8%
$-0.19vs$-0.17
Q4 24
-6.7%
$-0.16vs$-0.15
Q1 25
-50.0%
$-0.21vs$-0.14
Q2 25
0.0%
$-0.16vs$-0.16
Q3 25
-44.4%
$-3.90vs$-2.70
Q4 25
0.0%
$-2.70vs$-2.70
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-2.70 | $-2.70 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-2.70 | $-3.90 | -44.4% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.16 | $-0.16 | 0.0% | = MET |
Q1 2025 | Mar 31, 2025 | $-0.14 | $-0.21 | -50.0% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.15 | $-0.16 | -6.7% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.15 | $-0.21 | -40.0% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.20 | $-0.26 | -30.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.18 | $-0.26 | -44.4% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.13 | $-0.20 | -53.8% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.21 | $-0.18 | +14.3% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.19 | $-0.20 | -5.2% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | — | $-1.10 | — | — |
Q3 2022 | Sep 2, 2022 | — | $-0.03 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.54 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-2.04 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.55 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.54 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.26 | — | — |
Latest News
BioAffinity Technologies Chief Medical Officer To Present Data At American Cancer Society National Lung Cancer Roundtable On CyPath Lung Cytometry Test
📈 PositiveBenzinga•Dec 3, 2025, 01:08 PM
bioAffinity Technologies Q3 EPS $(4.74) Misses $(2.70) Estimate, Sales $1.446M Beat $1.411M Estimate
📉 NegativeBenzinga•Nov 14, 2025, 01:13 PM
bioAffinity Technologies Reports Continued Sales Growth For Its Noninvasive Lung Cancer Test, CyPath Lung, With Test Volumes More Than Doubling Since The Start Of 2025
📈 PositiveBenzinga•Nov 5, 2025, 01:08 PM
BIAF stock has given up its prior gain. bioAffinity Technologies shares were trading higher after the company announced the Australian Patent Office accepted its patent application for a platform to detect and characterize multiple lung diseases.
➖ NeutralBenzinga•Oct 28, 2025, 01:52 PM
bioAffinity Technologies shares are trading higher after the company announced the Australian Patent Office accepted its patent application for a platform to detect and characterize multiple lung diseases.
📈 PositiveBenzinga•Oct 28, 2025, 12:07 PM
bioAffinity Technologies Announces Acceptance Of Patent Application By Australian Patent Office For Its Platform To Detect And Characterize Multiple Lung Diseases
📈 PositiveBenzinga•Oct 28, 2025, 12:06 PM
BioAffinity Technologies Gets Notification Of Allowance From United States Patent and Trademark Office For New Patent Covering AI-Built Algorithm, Flow Cytometry Platform To Detect Lung Cancer
📈 PositiveBenzinga•Oct 16, 2025, 12:09 PM
bioAffinity Technologies Regains Nasdaq Compliance
📈 PositiveBenzinga•Oct 15, 2025, 12:06 PM
bioAffinity Technologies Reports Sales Of Its CyPath Lung Diagnostic Test For Lung Cancer Hit Record High In Q3 2025, Marking 95% Increase Over The Previous Quarter
📈 PositiveBenzinga•Oct 7, 2025, 12:08 PM
bioAffinity Technologies shares are trading lower after the company priced a $4.8M public offering of ~1.92M shares or pre-funded warrants at $2.50 per share.
📉 NegativeBenzinga•Sep 30, 2025, 02:34 PM
bioAffinity Technologies prices $4.8 million public offering; shares down over 30%
📉 NegativeSeeking Alpha•Sep 29, 2025, 08:01 PM
bioAffinity Technologies shares are trading lower after the company priced a $4.8M public offering of ~1.92M shares or pre-funded warrants at $2.50 per share.
📉 NegativeBenzinga•Sep 29, 2025, 07:56 PM
bioAffinity Technologies Shares Halted On Circuit Breaker To The Downside, Stock Now Down -30.81%
📉 NegativeBenzinga•Sep 29, 2025, 07:53 PM
bioAffinity Technologies Prices $4.8M Public Offering Of ~1.92M Shares Of Common Stock Or Pre-Funded Warrants At A Price Of $2.50/Share
➖ NeutralBenzinga•Sep 29, 2025, 07:53 PM
bioAffinity Technologies Shares Resume Trade
➖ NeutralBenzinga•Sep 26, 2025, 01:41 PM
bioAffinity Technologies shares are trading higher after the company announced that it released three additional case studies, with one case study demonstrating that CyPath Lung led to detecting Stage 1A lung cancer.
📈 PositiveBenzinga•Sep 26, 2025, 12:14 PM
bioAffinity Technologies Releases Three Additional Case Studies; One Case Study Includes CyPath Lung Detecting Stage 1A Lung Cancer
📈 PositiveBenzinga•Sep 26, 2025, 12:07 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 18, 2025, 11:50 PM
bioAffinity Technologies shares are trading lower after the company announced a 1-for-30 reverse stock split.
📉 NegativeBenzinga•Sep 17, 2025, 01:07 PM
bioAffinity Technologies announces 1-for-30 reverse stock split to regain Nasdaq compliance; shares down ~22%
📉 NegativeSeeking Alpha•Sep 17, 2025, 12:36 PM
Frequently Asked Questions about BIAF
What is BIAF's current stock price?
bioAffinity Technologies, Inc. (BIAF) is currently trading at $1.24 per share. The stock has moved +2.06% today.
What is the analyst price target for BIAF?
No analyst price targets are currently available for this stock.
What sector is bioAffinity Technologies, Inc. in?
bioAffinity Technologies, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is BIAF's market cap?
bioAffinity Technologies, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does BIAF pay dividends?
No, bioAffinity Technologies, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTL
Artelo Biosciences, Inc.
$1.57
Mkt Cap: $0.0B
CARM
Carisma Therapeutics, Inc.
$0.05
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
MNDR
Mobile-health Network Solutions Class A Ordinary Shares
$1.11
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
PTIX
Protagenic Therapeutics, Inc.
$1.19
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
WOK
WORK Medical Technology Group Ltd.
$0.05
Mkt Cap: $0.0B
Explore stocks similar to BIAF for comparison